LOW-DOSE ALEMTUZUMABHIGH-RISKREDUCED-INTENSITYPERIPHERAL-BLOODT-CELLSAlthough allogeneic hematopoietic cell transplantation (HCT) is currently the standard curative treatment for acute leukemia, relapse remains unacceptably high. Measurable (minimal) residual disease (MRD) after allogeneic HCT may be used as...
More recently, circulating tumor DNA (ctDNA) has gained attention as a new method of MRD assessment [132]. The advent of high-throughput sequencing (HTS)-based approaches has made it possible to detect small amounts of ctDNA that is continually shed into the bloodstream [133]. Preliminary d...
Other antibiotics used to treat S. suis infections in Europe were aminoglycosides (often combined with β-lactams), amphenicols, sulfonamides, and pleuromutilins. Reports have notified low or medium AMR rates. For example, aminoglycoside-resistance rates lower than 10% were continuously reported in ...
5,7 Although the financial aspects of delivering these novel therapies, especially in low- and middle-income countries where the SCD burden is highest,1 are beyond the scope of this review, it is worth noting that autologous gene therapies provide several advantages and an opportunity to leapfrog...
an extremely fast destruction of red blood cells, which can be lethal. This is why healthcare providers need to carefully check blood types before giving blood. Some causes of hemolytic anemia are temporary.Hemolytic anemia may be curableif a doctor can identify the underlying cause and treat ...
ACE inhibitors is a class of drugs prescribed to control high blood pressure; and for the treatment and prevention of heart attacks, heart failure, and prevent kidney disease. Common side effects are headache, cough, rash, dizziness, and chest pain. Drug
30 Our patient was treated with gilteritinib as a bridge to allogeneic HCT. Of note, she initially was not a candidate for allogeneic HCT because her disease was classified as favorable-risk AML according to 2017 ELN criteria (NPM1mut and FLT3-ITDlow) with molecular CR1. After allogeneic ...
Cook and Phillips provide their expert views on how to treat patients with adult T-cell leukemia/lymphoma (ATL), an uncommon complication of long-term infection with human T-lymphotropic virus type 1. Using 4 cases to orient clinicians to the diversity of presentation and management strategies of...
S. Food and Drug Administration (FDA) approved 45 novel drugs, including four used to treat multiple myeloma5. About a decade ago, most chemotherapies were limited to conventional pan-cytotoxic drugs that targeted DNA or microtubules such as the CHOP regimen (cyclophosphamide, hydroxydaunorubicin, ...
primary refractory leukemia or an early relapse (<6 months from first remission or transplant) to single-agent quizartinib vs investigator’s choice of salvage chemotherapy (SC): fludarabine, cytarabine, filgrastim, idarubicin (FLAG-IDA), mitoxantrone, etoposide, cytarabine (MEC), or low-dose ...